Calcitonin intranasal - Unigene

Drug Profile

Calcitonin intranasal - Unigene

Alternative Names: Fortical Intranasal; Nasal calcitonin - Unigene; Recombinant salmon calcitonin intranasal; Salcatonin intranasal - Unigene; sCT nasal

Latest Information Update: 18 Mar 2013

Price : $50

At a glance

  • Originator Unigene Laboratories
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Postmenopausal osteoporosis

Most Recent Events

  • 11 Mar 2013 The US FDA Advisory Committe concludes that the benefits of calcitonin products do not outweigh the risks, and should not continue to be broadly marketed
  • 07 Jun 2011 Unigene terminates its involvement in Unigene Biotechnology (the China Joint Venture) and recovers all intellectual property rights granted under the agreement with Shijiazhuang Pharmaceutical Group
  • 03 Apr 2008 Phase-III clinical trials in Postmenopausal osteoporosis (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top